KEO Energy said its U.S. subsidiary signed the PetroUrdaneta operating framework with PDVSA, including service, payment administration and financing agreements that can provide up to $350 million for the Venezuelan joint venture.

Six-month TRANQUILITY data showed sustained hs-CRP reductions across monthly and quarterly pacibekitug regimens, supporting further Phase 3 cardiovascular evaluation.

The 948-patient ENRICH-AF trial found no significant reduction in stroke or systemic embolism with edoxaban, while major bleeding rose to 11.6% from 5.2%.

Lyntris has finished a multi-year investment in phase change material manufacturing at its Jessup, Maryland operation, with production capacity for seeker, sensor and mission-electronics thermal hardware available in Q3 2026.

Moderna increased its 2032 convertible-note sale from $2.0 billion to $2.6 billion, with net proceeds expected to support general corporate purposes after funding a $285 million capped-call hedge.

The FDA expanded Mounjaro’s label to reduce major adverse cardiovascular event risk in adults with type 2 diabetes who are at high risk, adding a new clinical and commercial claim for Eli Lilly’s blockbuster drug.

Teva will set the floor in BioXcel’s bankruptcy auction for IGALMI and BXCL501, with additional milestone payments tied to FDA approval timing and future sales.

BRC Group Holdings will redeem all $142.1 million of its RILYN senior notes on Sept. 29 at par plus accrued interest, ending trading in the issue one day before its scheduled maturity.

The discount retailer raised full-year guidance after second-quarter same-store sales grew 3.5% and diluted EPS climbed 33.3%, though tariff refunds provided a notable one-time lift to margins.

Burlington lifted its full-year adjusted EPS forecast after second-quarter earnings beat expectations, though management said tariff refunds will be reinvested into sharper prices for shoppers rather than kept as a lasting profit boost.